1 / 9Pfizer CEO Albert Bourla on Monday said a vaccine that targets the omicron variant of Covid will be ready in March, and the company’s already begun manufacturing the doses.2 / 9Pfizer Chief Executive Officer Albert Bourla told CNBC that Pfizer is already manufacturing doses due to keen interest from governments, as authorities contend with huge Covid-19 infection counts, including large numbers of 'breakthrough' Omicron cases in vaccinated populations.3 / 9'This vaccine will be ready in March,' Bourla told the network. 'I don't know if we will need it. I don't know if and how it will be used.'4 / 9Bourla said the existing regime of two vaccine shots and a booster has provided 'reasonable' protection against serious health effects from Omicron.5 / 9But a vaccine focused directly on the Omicron variant would also guard against breakthrough infections of a strain that has proven highly contagious, but has also resulted in many mild or asymptomatic cases.6 / 9In a separate interview with CNBC Monday, Moderna CEO Stephane Bancel said the company is developing a booster that could address Omicron and other emerging strains in the fall 2022.7 / 9'We are discussing with public health leaders around the world to decide what we think is the best strategy for a potential booster for the fall of 2022,' Bancel told the network.8 / 9'We need to be careful to try to stay ahead of a virus and not behind the virus.'9 / 9Medication given to high-risk adults after the initial onset of coronary heart disease is said to reduce the number of hospitalizations and deaths by about 89 percent.